Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Q1 Earnings Top, Biopharma Gains From Coronavirus

by Zacks Equity Research

Pfizer (PFE) beats estimates for earnings. While the coronavirus pandemic hurts sales of some Pfizer medicines, it benefited sales of others, resulting in a net positive benefit on total sales.

Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.

What's in the Cards for Pfizer (PFE) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.

Why Mylan (MYL) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Novartis Terminates Sale of Sandoz Dermatology Business

by Zacks Equity Research

Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.

Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma

by Zacks Equity Research

Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.

Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Indrajit Bandyopadhyay headshot

Pharma, Biotech Players Step Up Efforts Against Coronavirus

by Indrajit Bandyopadhyay

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

by Zacks Equity Research

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

Novartis to Donate Generic Hydroxychloroquine for Coronavirus

by Zacks Equity Research

Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

Ekta Bagri headshot

Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus

by Ekta Bagri

Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

by Zacks Equity Research

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

Mylan (MYL) Tops Q4 Earnings Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 8.53% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat

by Zacks Equity Research

Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

Is a Surprise Coming for Mylan (MYL) This Earnings Season?

by Zacks Equity Research

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

Air Transport (ATSG) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Low fuel costs are likely to have aided Air Transport Services' (ATSG) fourth-quarter earnings performance.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

Manaswita Ghosh Dutta headshot

3 Best Drugmakers That Are Immune to Coronavirus Fright

by Manaswita Ghosh Dutta

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.

What's in Store for Acorda (ACOR) This Earnings Season?

by Zacks Equity Research

During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

by Zacks Equity Research

The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.